Regeneron Pharmaceuticals, Inc. with ticker code (REGN) have now 25 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $1,300.00 and $820.00 with the average share target price sitting at $1,152.39. (at the time of writing). Now with the previous closing price of $928.90 and the analysts are correct then there would likely be a percentage uptick in value of 24.1%. The 50 day moving average now sits at $1,088.33 and the 200 day MA is $1,014.22. The market cap for the company is 103.77B. The stock price is currently at: $933.02 USD
The potential market cap would be $128,740,760,894 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 24.69, revenue per share of $125.83 and a 7.61% return on assets.
Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. The Company also provides Expresse service assurance and CloudCheck WiFi experience management solutions.
